From a therapeutic perspective, our results provide a strategy to improve immune responses in ovarian cancer and establish a rationale for the use of DPP4 inhibitors as a rapidly translatable second-line treatment for this disease. This evidence concerns the gene DPP4 and ovarian carcinoma.